 Joseph Schacht
Concepts (177)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alcoholism | 26 | 2025 | 765 | 5.890 |
Why?
| | Naltrexone | 7 | 2021 | 87 | 2.950 |
Why?
| | Cues | 17 | 2025 | 325 | 2.140 |
Why?
| | Catechol O-Methyltransferase | 4 | 2022 | 18 | 2.130 |
Why?
| | Dopamine Plasma Membrane Transport Proteins | 5 | 2021 | 47 | 2.000 |
Why?
| | Alcohol Drinking | 17 | 2025 | 763 | 1.660 |
Why?
| | Receptors, Opioid, mu | 5 | 2021 | 65 | 1.540 |
Why?
| | Marijuana Abuse | 8 | 2019 | 233 | 1.400 |
Why?
| | Narcotic Antagonists | 4 | 2021 | 164 | 1.370 |
Why?
| | Polymorphism, Single Nucleotide | 9 | 2020 | 2063 | 1.060 |
Why?
| | Craving | 5 | 2025 | 40 | 1.060 |
Why?
| | Brain | 17 | 2025 | 2669 | 1.050 |
Why?
| | Substance Withdrawal Syndrome | 5 | 2019 | 176 | 1.010 |
Why?
| | gamma-Aminobutyric Acid | 4 | 2019 | 168 | 1.000 |
Why?
| | Pharmacogenomic Variants | 3 | 2017 | 35 | 0.790 |
Why?
| | Magnetic Resonance Imaging | 18 | 2024 | 3386 | 0.790 |
Why?
| | Flumazenil | 2 | 2013 | 8 | 0.790 |
Why?
| | Cyclohexanecarboxylic Acids | 2 | 2013 | 22 | 0.770 |
Why?
| | Amines | 2 | 2013 | 38 | 0.770 |
Why?
| | Reward | 5 | 2020 | 240 | 0.730 |
Why?
| | Alcohol Deterrents | 2 | 2018 | 17 | 0.720 |
Why?
| | Aripiprazole | 2 | 2017 | 17 | 0.720 |
Why?
| | Dopamine Agonists | 2 | 2017 | 39 | 0.700 |
Why?
| | Substance-Related Disorders | 3 | 2024 | 1019 | 0.620 |
Why?
| | Cocaine | 1 | 2021 | 149 | 0.620 |
Why?
| | Receptor, Cannabinoid, CB1 | 4 | 2012 | 40 | 0.610 |
Why?
| | Functional Neuroimaging | 4 | 2024 | 73 | 0.610 |
Why?
| | Dopamine | 2 | 2022 | 287 | 0.580 |
Why?
| | Polymorphism, Genetic | 2 | 2018 | 639 | 0.560 |
Why?
| | Cognition | 3 | 2018 | 1122 | 0.530 |
Why?
| | Epigenesis, Genetic | 1 | 2021 | 616 | 0.530 |
Why?
| | Dopamine Agents | 1 | 2016 | 16 | 0.520 |
Why?
| | Glutamic Acid | 5 | 2019 | 235 | 0.490 |
Why?
| | Prefrontal Cortex | 2 | 2016 | 303 | 0.490 |
Why?
| | Ethanol | 6 | 2024 | 589 | 0.480 |
Why?
| | Nicotine | 1 | 2018 | 302 | 0.480 |
Why?
| | Brain Mapping | 4 | 2017 | 574 | 0.480 |
Why?
| | Amidohydrolases | 3 | 2009 | 30 | 0.460 |
Why?
| | Motivation | 6 | 2020 | 546 | 0.450 |
Why?
| | Benzazepines | 1 | 2014 | 39 | 0.440 |
Why?
| | Quinoxalines | 1 | 2014 | 64 | 0.430 |
Why?
| | Smoking | 2 | 2018 | 1499 | 0.420 |
Why?
| | Nicotinic Agonists | 1 | 2014 | 123 | 0.400 |
Why?
| | Adult | 28 | 2025 | 35497 | 0.400 |
Why?
| | Cannabis | 1 | 2018 | 463 | 0.370 |
Why?
| | Humans | 43 | 2025 | 129271 | 0.360 |
Why?
| | Marijuana Smoking | 2 | 2019 | 247 | 0.360 |
Why?
| | Gyrus Cinguli | 5 | 2025 | 79 | 0.350 |
Why?
| | Alcohol-Related Disorders | 1 | 2012 | 118 | 0.350 |
Why?
| | Male | 30 | 2025 | 63517 | 0.350 |
Why?
| | Amygdala | 1 | 2012 | 198 | 0.350 |
Why?
| | Genotype | 6 | 2020 | 1835 | 0.350 |
Why?
| | Young Adult | 17 | 2020 | 12392 | 0.340 |
Why?
| | Female | 30 | 2025 | 68556 | 0.340 |
Why?
| | Genetic Variation | 2 | 2012 | 938 | 0.330 |
Why?
| | Catechol O-Methyltransferase Inhibitors | 2 | 2022 | 3 | 0.330 |
Why?
| | Corpus Striatum | 1 | 2011 | 159 | 0.320 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2011 | 253 | 0.310 |
Why?
| | Glutamine | 2 | 2019 | 99 | 0.300 |
Why?
| | Treatment Outcome | 7 | 2021 | 10202 | 0.300 |
Why?
| | Genetic Predisposition to Disease | 2 | 2018 | 2276 | 0.300 |
Why?
| | Hippocampus | 1 | 2012 | 871 | 0.270 |
Why?
| | Heterozygote | 2 | 2018 | 272 | 0.260 |
Why?
| | Receptors, Dopamine D2 | 2 | 2017 | 90 | 0.260 |
Why?
| | Middle Aged | 12 | 2025 | 31091 | 0.260 |
Why?
| | Acetaldehyde Dehydrogenase Inhibitors | 1 | 2025 | 1 | 0.240 |
Why?
| | Aldehyde Dehydrogenase, Mitochondrial | 1 | 2025 | 23 | 0.240 |
Why?
| | Antipsychotic Agents | 2 | 2017 | 195 | 0.230 |
Why?
| | Benzamides | 1 | 2025 | 207 | 0.220 |
Why?
| | Benzodioxoles | 1 | 2025 | 105 | 0.220 |
Why?
| | Neuroimaging | 2 | 2024 | 278 | 0.210 |
Why?
| | Pharmacogenetics | 2 | 2016 | 172 | 0.210 |
Why?
| | Glutathione | 1 | 2025 | 347 | 0.210 |
Why?
| | Nerve Net | 2 | 2018 | 260 | 0.210 |
Why?
| | Behavior, Addictive | 3 | 2019 | 80 | 0.200 |
Why?
| | Cartilage Oligomeric Matrix Protein | 1 | 2021 | 2 | 0.190 |
Why?
| | Gene Frequency | 2 | 2016 | 502 | 0.190 |
Why?
| | Biomarkers | 3 | 2024 | 3968 | 0.180 |
Why?
| | Checklist | 1 | 2022 | 92 | 0.180 |
Why?
| | Adolescent | 12 | 2024 | 20315 | 0.180 |
Why?
| | Ventral Striatum | 1 | 2020 | 9 | 0.180 |
Why?
| | Anesthesia, General | 1 | 2021 | 54 | 0.170 |
Why?
| | Double-Blind Method | 3 | 2025 | 1875 | 0.170 |
Why?
| | Appointments and Schedules | 1 | 2021 | 84 | 0.170 |
Why?
| | Aspartic Acid | 2 | 2019 | 80 | 0.160 |
Why?
| | Alcohol Abstinence | 1 | 2019 | 13 | 0.160 |
Why?
| | Elective Surgical Procedures | 1 | 2021 | 164 | 0.160 |
Why?
| | Drug Therapy, Combination | 2 | 2013 | 1040 | 0.160 |
Why?
| | Homozygote | 2 | 2016 | 193 | 0.160 |
Why?
| | Binge Drinking | 1 | 2019 | 37 | 0.150 |
Why?
| | Therapy, Computer-Assisted | 1 | 2019 | 60 | 0.150 |
Why?
| | Avoidance Learning | 1 | 2019 | 70 | 0.150 |
Why?
| | Glycine | 1 | 2019 | 165 | 0.150 |
Why?
| | Transferrin | 1 | 2018 | 42 | 0.150 |
Why?
| | Frontal Lobe | 1 | 2019 | 153 | 0.150 |
Why?
| | Follow-Up Studies | 3 | 2018 | 4887 | 0.140 |
Why?
| | Receptors, Dopamine D4 | 1 | 2017 | 26 | 0.140 |
Why?
| | Minisatellite Repeats | 1 | 2017 | 40 | 0.140 |
Why?
| | Sialoglycoproteins | 1 | 2018 | 155 | 0.140 |
Why?
| | Self Administration | 1 | 2017 | 120 | 0.140 |
Why?
| | Proton Magnetic Resonance Spectroscopy | 3 | 2025 | 21 | 0.140 |
Why?
| | Central Nervous System Depressants | 1 | 2017 | 82 | 0.140 |
Why?
| | Case-Control Studies | 3 | 2019 | 3377 | 0.140 |
Why?
| | Severity of Illness Index | 2 | 2017 | 2740 | 0.140 |
Why?
| | Drug Interactions | 1 | 2018 | 393 | 0.130 |
Why?
| | Self-Control | 1 | 2017 | 55 | 0.130 |
Why?
| | Recurrence | 3 | 2020 | 1005 | 0.130 |
Why?
| | Single-Blind Method | 1 | 2017 | 271 | 0.130 |
Why?
| | DNA Methylation | 1 | 2021 | 610 | 0.130 |
Why?
| | Receptors, Dopamine D1 | 1 | 2016 | 29 | 0.130 |
Why?
| | Impulsive Behavior | 1 | 2017 | 127 | 0.130 |
Why?
| | Predictive Value of Tests | 1 | 2021 | 1949 | 0.130 |
Why?
| | Hemodynamics | 1 | 2021 | 1090 | 0.120 |
Why?
| | Stress, Psychological | 1 | 2024 | 1066 | 0.120 |
Why?
| | Visual Perception | 1 | 2017 | 162 | 0.120 |
Why?
| | Receptors, GABA-A | 1 | 2016 | 126 | 0.120 |
Why?
| | Cocaine-Related Disorders | 1 | 2015 | 108 | 0.110 |
Why?
| | Attention | 1 | 2018 | 438 | 0.110 |
Why?
| | Adolescent Behavior | 1 | 2019 | 506 | 0.110 |
Why?
| | Varenicline | 1 | 2014 | 25 | 0.110 |
Why?
| | Neuropsychological Tests | 1 | 2018 | 1014 | 0.110 |
Why?
| | Pilot Projects | 2 | 2019 | 1584 | 0.100 |
Why?
| | Tobacco Use Disorder | 1 | 2015 | 236 | 0.100 |
Why?
| | GABA Modulators | 1 | 2013 | 12 | 0.100 |
Why?
| | Tandem Repeat Sequences | 1 | 2012 | 18 | 0.100 |
Why?
| | Excitatory Amino Acid Antagonists | 1 | 2013 | 100 | 0.100 |
Why?
| | Sex Factors | 1 | 2018 | 1965 | 0.100 |
Why?
| | Patient Selection | 1 | 2016 | 662 | 0.100 |
Why?
| | Precision Medicine | 1 | 2016 | 386 | 0.100 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 1 | 2012 | 77 | 0.100 |
Why?
| | Basal Ganglia | 1 | 2012 | 53 | 0.100 |
Why?
| | Secondary Prevention | 1 | 2013 | 218 | 0.090 |
Why?
| | Prognosis | 2 | 2017 | 3773 | 0.090 |
Why?
| | Surveys and Questionnaires | 3 | 2016 | 5384 | 0.090 |
Why?
| | Functional Laterality | 1 | 2012 | 222 | 0.090 |
Why?
| | Longitudinal Studies | 1 | 2018 | 2716 | 0.090 |
Why?
| | Chi-Square Distribution | 1 | 2012 | 514 | 0.090 |
Why?
| | Positron-Emission Tomography | 1 | 2012 | 286 | 0.090 |
Why?
| | Data Interpretation, Statistical | 1 | 2012 | 336 | 0.090 |
Why?
| | Genetic Association Studies | 1 | 2012 | 361 | 0.080 |
Why?
| | Prospective Studies | 2 | 2018 | 7123 | 0.080 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2023 | 2439 | 0.080 |
Why?
| | Linear Models | 1 | 2011 | 819 | 0.070 |
Why?
| | Opioid-Related Disorders | 1 | 2015 | 483 | 0.070 |
Why?
| | Phenotype | 1 | 2016 | 3074 | 0.070 |
Why?
| | Protein Binding | 1 | 2012 | 2120 | 0.060 |
Why?
| | Alleles | 2 | 2020 | 845 | 0.060 |
Why?
| | Proof of Concept Study | 1 | 2025 | 69 | 0.060 |
Why?
| | Gene Expression | 1 | 2008 | 1466 | 0.050 |
Why?
| | Glucagon-Like Peptide-1 Receptor | 1 | 2023 | 92 | 0.050 |
Why?
| | Administration, Oral | 1 | 2025 | 785 | 0.050 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2020 | 1365 | 0.050 |
Why?
| | Reproducibility of Results | 2 | 2022 | 3080 | 0.050 |
Why?
| | Delphi Technique | 1 | 2022 | 225 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2025 | 2011 | 0.040 |
Why?
| | Cross-Sectional Studies | 2 | 2025 | 5051 | 0.040 |
Why?
| | Aged | 1 | 2018 | 22032 | 0.040 |
Why?
| | Oxidative Stress | 1 | 2025 | 1266 | 0.040 |
Why?
| | Photic Stimulation | 1 | 2019 | 240 | 0.040 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2024 | 574 | 0.040 |
Why?
| | Animals | 2 | 2016 | 35309 | 0.030 |
Why?
| | Reaction Time | 1 | 2018 | 410 | 0.030 |
Why?
| | Principal Component Analysis | 1 | 2016 | 190 | 0.030 |
Why?
| | Memory, Short-Term | 1 | 2018 | 263 | 0.030 |
Why?
| | Self Report | 1 | 2019 | 795 | 0.030 |
Why?
| | Oxygen | 2 | 2009 | 915 | 0.030 |
Why?
| | Valproic Acid | 1 | 2014 | 47 | 0.030 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2016 | 538 | 0.030 |
Why?
| | Taurine | 1 | 2014 | 43 | 0.030 |
Why?
| | Pregnancy | 1 | 2024 | 6391 | 0.020 |
Why?
| | Child | 2 | 2024 | 20785 | 0.020 |
Why?
| | Age Factors | 1 | 2018 | 3140 | 0.020 |
Why?
| | DNA Mutational Analysis | 1 | 2009 | 385 | 0.020 |
Why?
| | Cannabinoids | 1 | 2009 | 153 | 0.020 |
Why?
| | Dronabinol | 1 | 2008 | 203 | 0.020 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2009 | 742 | 0.010 |
Why?
| | Genomics | 1 | 2008 | 717 | 0.010 |
Why?
|
|
Schacht's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|